Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
By Staff Reporters
MAY THE FOURTH BE WITH YOU
***
***
Many pharma companies reported earnings in the last week, and the common thread is crashing Covid-related sales.
For example, AstraZeneca’s Covid medication sales dropped $1.5b in Q1, Merck’s Covid antiviral sales fell 88% from the same quarter in 2022, and Roche’s diagnostics division sales fell 28% from Q1 2022, thanks to low Covid-test demand. Clearly, pharma companies have to figure out how to pivot their strategies in a post-Covid world.
CITE: https://www.r2library.com/Resource
***
The CDC will not continue to track Covid-19 community spread as the country enters the endemic stage of the pandemic.
***
The Food and Drug Administration approved Wednesday the first-ever vaccine to combat severe respiratory syncytial virus, or RSV. Arexvy, the new vaccine developed by GlaxoSmithKline, was approved for adults 60 and older and was 82% effective at preventing lower respiratory tract illness caused by RSV, according to trial data. It was also 94% effective in those who had at least one underlying medical condition.
***
The Federal Reserve voted unanimously to raise interest rates by a quarter point yesterday, the tenth rate hike since the central bank started its battle against inflation last March. The move comes amid ongoing fragility in the banking sector triggered partly by higher interest rates, and following the collapse of three regional banks. Markets had anticipated the rate hike, and remained fairly muted after the Fed’s announcement.
***
Finally, here’s where the major indexes ended up:
- The S&P 500® Index was down 28.83 points at 4090.75; the Dow Jones industrial average was down 270.29 (0.8%) at 33,414.24; the NASDAQ Composite was down 55.18 (0.5%) at 12,025.33.
- The 10-year Treasury yield was down about 7 basis points at 3.367%.
- CBOE’s Volatility Index was up 0.52 at 18.30.
Energy companies were among the market’s weakest performers as crude oil continued a recent decline, with WTI crude futures falling more than 4% under $70 a barrel—a nearly six-week low.
Semiconductor and financial shares were also weak. The U.S. dollar index dropped sharply in the wake of the Fed announcement before rebounding.
***
***
***
COMMENTS APPRECIATED
Thank You
***
Share this:
Filed under: "Ask-an-Advisor", Alerts Sign-Up, Drugs and Pharma, Health Economics, Health Insurance, Investing | Tagged: Arexvy, Big Pharma, covid, DJIA, DOW, FDA, Federal Reserve, FOMC, Food Drug Administration, GlaxoSmithKline, gold, inflation, interest rates, Merck, NASDAQ, oil, pharma, Respiratory syncytial virus, Roche, RSV, Russell 2000, S&P 500, Treasury yields |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Leave a Reply